Development of an UNC13A antisense oligonucleotide treatment for ALS and FTD

Ended Project Grant Awarded Last action

Award ID
HT94252310469
Recipient
Awarding agency
Obligated
$839,898

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Place of performance
Monrovia, CA 91016, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

Acurastem Inc. received a $839,898.40 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop an UNC13A antisense oligonucleotide treatment for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) from June 1, 2023 to May 31, 2025. The grant funding will support Acurastem's efforts to advance a novel gene therapy targeting UNC13A, a gene implicated in ALS and FTD, using antisense oligonucleotide technology. This award furthers Acurastem's ongoing work developing antisense oligonucleotide treatments for neurodegenerative diseases, having previously received over $15 million from federal agencies including the National Institutes of Health to target genes such as SYF2 and PIKFYVE for ALS and FTD indications.

Quick answers

Who received award HT94252310469?

HT94252310469 was awarded to Acurastem Incorporated by Defense Health Agency (Department of Defense) on June 1, 2023.

How much is award HT94252310469 worth?

$839,898 has been obligated on HT94252310469.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login